People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...
ALTUVIIIO is a first-in-class, high-sustained factor VIII replacement therapy which provides highly effective bleed protection in adults and children with hemophilia A Approval demonstrates commitment ...
Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec induced endogenous factor VIII production and significantly reduced bleeding and ...
Hemophilia A, also known as classic hemophilia or factor VIII deficiency, is a bleeding disorder. It occurs when certain proteins are missing in the blood, causing people to bleed and bruise easily.
Factor replacement therapy is the primary treatment for people with hemophilia A. But a doctor may also prescribe a combination of other medications and physical therapy. Hemophilia A is a severe ...
Please provide your email address to receive an email when new articles are posted on . The novel gene therapy SPK-8011 induced sustained factor VIII expression in patients with hemophilia A, ...
AFSTYLA ®, Antihemophilic Factor (Recombinant), Single Chain, is contraindicated in patients who have had life-threatening hypersensitivity reactions to AFSTYLA or its excipients, or to hamster ...
Altuviiio temporarily replaces the missing coagulation factor VIII needed for effective hemostasis. The Food and Drug Administration (FDA) has approved Altuviiio ™ (antihemophilic factor [recombinant] ...
Valoctocogene roxaparvovec delivers a B-domain–deleted factor VIII coding sequence with an adeno-associated virus vector to prevent bleeding in persons with severe hemophilia A. The findings of a ...
Once-weekly efanesoctocog alfa provides high sustained factor VIII activity with superior bleeding prevention as compared with prestudy factor VIII prophylaxis in previously treated patients 12 years ...
The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO®[Antihemophilic Factor (Recombinant), Fc-VWF XTEN Fusion Protein], a first-in-class, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results